DelveInsight’s Diabetic Peripheral Neuropathy Pipeline Insights 2022 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from Diabetic Peripheral Neuropathy Pipeline Report
Download a PDF Sample Copy of the Diabetic Peripheral Neuropathy Clinical Trials Report, visit here- Diabetic Peripheral Neuropathy Pipeline Outlook
Diabetic Peripheral Neuropathy Overview
Diabetic neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs and feet, it is known as diabetic peripheral neuropathy.Diabetic peripheral neuropathy is different from peripheral arterial disease (poor circulation), which affects the blood vessels rather than the nerves. Three different groups of nerves can be affected by diabetic neuropathy:
Diabetic Peripheral Neuropathy Treatment
First and foremost, treatment of diabetic peripheral neuropathy centers on control of the patient’s blood sugar level. In addition, various options are used to treat the painful symptoms. Medications are available to help relieve specific symptoms, such as tingling or burning. Sometimes a combination of different medications is used. In some cases, the patient may also undergo physical therapy to help reduce balance problems or other symptoms.
Diabetic Peripheral Neuropathy Emerging Drugs Profile
ZhongQi Pharmaceutical Technology is conducting a multiple doses study to evaluate the safety, tolerability, pharmacokinetics (including food effect) of SYHA1402 in healthy subjects. This study consists of two parts: The objective of the food effect study (Part 1) is to investigate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The primary objective of the multiple doses study (Part 2) is to investigate safety, tolerability and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of Multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses.
VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms – a configuration that closely mimics HGF productions in humans that is needed for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wildtype human HGF proteins.
NYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for the treatment of chronic pain. Dysregulation of glutamatergic circuits in the brain is involved in the development of centralized chronic pain. NYX-2925 is in late stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia.
LX9211 is a potent, orally delivered, selective small molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain. Lexicon has exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1.
Get to know more information of the Diabetic Peripheral Neuropathy Emerging Therapies and Companies- Diabetic Peripheral Neuropathy Ongoing Clinical Trials Analysis
Diabetic Peripheral Neuropathy Pipeline Phases
DelveInsight’s Report covers around 10+ products under different phases of clinical development like
Diabetic Peripheral Neuropathy Pipeline Analysis
The report provides insights into:-
Diabetic Peripheral Neuropathy Pipeline Therapeutic Analysis
There are approx. 20+ key companies which are developing the therapies for Diabetic Peripheral Neuropathy. The companies which have their Diabetic Peripheral Neuropathy drug candidates in the most advanced stage, i.e. phase III include, Helixmith Co., Ltd. and Daiichi Sankyo.
Scope of the Diabetic Peripheral Neuropathy Pipeline Report
To know more facts about the Diabetic Peripheral Neuropathy Pipeline Insights Report, View Here- Diabetic Peripheral Neuropathy Unmet Needs and Analyst Views
Table of Content
Related Report- Acoustic Neuroma Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market